A new tuberculosis vaccine has been developed by researchers. The new vaccine was developed to act as a booster to Bacille Calmette Guerin (BCG), currently the only TB vaccine available.
The vaccine, based on a genetically modified cold virus, was developed in the lab of Zhou Xing, professor of pathology and molecular medicine and the McMaster Immunology Research Centre, who co-led the phase one study with Dr. Fiona Smaill, professor and chair of the Department of Pathology and Molecular Medicine of the Michael G. DeGroote School of Medicine at McMaster.
Screening Tests for Tuberculosis
Tuberculin skin test and Interferon - Release Assays are tests used to screen for tuberculosis.
Advertisement
BCG was developed in the 1920s and has been used worldwide. The new "booster" would reactivate immune elements that over time diminish following BCG vaccination.
The findings have been published in the journal Science Translational Medicine.
Source: ANI
Source: ANI
Tuberculosis
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to other organs.
Advertisement
 Quiz on TuberculosisTuberculosis is a major health care concern, especially in Africa and South East Asia. Brush up your information on tuberculosis by taking this quiz. | Advertisement
|
Most Promising Tuberculosis Vaccine Proved Unsuccessful in Large Scale Trials
Doctors had high hopes for the formula but the most promising vaccine to replace the world's 91-year-old TB jab does not protect against the disease, large-scale trials showed.
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.